AzTrials
AzTrials

Asymptomatic Carotid Artery StenosisACTRISNCT02841098

" Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "

A study testing Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone in people with Asymptomatic Carotid Artery Stenosis, run by Centre Hospitalier St Anne at 23 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Asymptomatic Carotid Artery Stenosis
What is being tested?
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
43 participants
Where
23 sitesFrance
Study dates
16 Sep 2019to 13 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 50 years or over
  • No ipsilateral stroke or TIA within 180 days of randomization
  • Atherosclerotic carotid stenosis between 70 and 99% (NASCET method)
  • At least one of the following markers of ipsilateral stroke risk:
  • Silent brain infarction on MRI, DWi, consistent with embolism from or hemodynamic consequences of the qualifyiing stenosis
  • History of contralateral TIA or ischemic stroke due to atherosclerotic carotid disease
Show all 13Show fewer
  • Predominantly echolucent plaque on ultrasound
  • Rapid (within 1 year) carotid stenosis progresion
  • TCD-detected microembolic signals
  • Impairment of TCD-measured cerebral vasomotor reserve
  • Intraplaque haemorrhage on magnetic resonance imaging
  • Rapid and severe stenosis progression
  • Patient is able and willing to give informed consent

Who cannot join

  • Previous revascularization procedure in the artery to be randomised
  • Patients not suitable for endarterectomy due to anatomical factors
  • Carotid stenosis caused by non-atherosclerotic disease e.g. neck radiotherapy or fibromuscular disease
  • Patients who have had contralateral carotid artery or vertebral artery or intracranial artery revascularisation within 6 weeks prior to randomisation
  • Patients with planned revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery within 6 weeks after randomisation or the date of CEA
  • Patients who have had coronary artery bypass grafting within 3 months prior to randomisation or other major surgery within 6 weeks prior to randomisation
Show all 13Show fewer
  • Patients with planned coronary artery bypass grafting or other major surgery within 6 weeks after CEA of the artery considered for treatment in the trial
  • Patients with pre-existing disability (modified Rankin score greater than 2)
  • Patients who have a low 5-year life expectancy (see appendix for definition)
  • Patients intolerant or allergic to all of the medications available for OMT
  • Patients in clinical trials of investigational medicinal products or who have been in clinical trials within the last 4 months will not be enrolled unless otherwise agreed
  • Patients who are known to be pregnant
  • Patients unwilling or unable to participate in follow-up

Trial locations and contacts

23 sites in 1 country.

23 sites in 1 country

France23 sites
  • Centre Hospitalier régional de Besançon, Hôpital Jean Minjoz

    Besançon, 25030

  • CHU Bordeaux, Groupe Hospitalier Pellegrin

    Bordeaux, 33076

  • CHRU La Cavale Blanche

    Brest, 29200

  • Hôpital Gabriel Montpied

    Clermont-Ferrand, 63003

  • CHU Henri Mondor

    Créteil, 94010

  • CHU Dijon-Bourgogne

    Dijon, 21079

  • CHU de Grenoble

    Grenoble, 38043

  • Hôpital Mignot - CH Versailles

    Le Chesnay, 78150

  • CHRU de Lille

    Lille, 59037

  • Hôpital Neurologique Pierre Wertheimer GHE

    Lyon, 69677

  • Hôpital Gui de Chauliac

    Montpellier, 34 295

  • CHU de Nice, Hôpital Pasteur 2

    Nice, 06000

  • Hôpital Lariboisière

    Paris, 75010

  • Hôpital Saint-Antoine

    Paris, 75012

  • Groupe Hospitalier Pitié-Salpétrière

    Paris, 75013

  • Centre Hospitalier Sainte-Anne

    Paris, 75014

  • Centre Hospitalier Bichat-Claude Bernard

    Paris, 75018

  • CHU La Milétrie

    Poitiers, 86021

  • Hôpital Pontchaillou CHU Rennes

    Rennes, 35033

  • CHU de Rouen, Hôpital Charles Nicolle

    Rouen, 76031

  • Hôpital Nord CHU Saint-Etienne

    Saint-Etienne, 42055

  • CHU de Strasbourg, Hôpital de Hautpierre

    Strasbourg, 67098

  • CHU de Toulouse Hôpital Pierre-Paul Riquet

    Toulouse, 31059

Other trials in France

About this study

Official title: " Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "

The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone.

Read the detailed description

Carotid artery stenosis >= 50% affects about 3% of subjects >= 60 years and accounts for up to 15% of all ischemic strokes. Overall, patients with asymptomatic carotid stenosis have a low risk of ipsilateral stroke on modern medical therapy. It is therefore uncertain whether the benefit of carotid surgery still justifies the perioperative risk of stroke or death, and whether revascularisation is good value for money considering competing demands on health services. Several imaging techniques have been developed to identify patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke. Specifically, the presence of transcranial Doppler (TCD)-detected embolic signals, intraplaque haemorrhage on magnetic resonance imaging, TCD-measured impaired cerebral vasomotor reserve or rapid stenosis progression have all been shown to involve an at least 3-fold higher risk of ipsilateral stroke. However, before recommendations for clinical practice can be made regarding the use of these tools, their utility must be demonstrated in a formal randomised clinical trial. Our hypothesis is that the use of these predictors can identify a subset of patients with asymptomatic carotid stenosis who could benefit from prophylactic endarterectomy.

Carotid endarterectomy The procedure will be carried out with the technique routinely used by each surgeon. Operative reports and perioperative complications will be collected. CEA will have to be performed as soon as possible, within 60 days after randomization.

Optimal medical therapy OMT will be applied to all patients and started immediately after randomisation.

OMT will be defined by the adhoc committee and follow relevant guidelines. It will include:

  • Antiplatelet therapy. If the patient requires anticoagulation for any reason (e.g. atrial fibrillation), the patient should be treated with an appropriate anticoagulant according to the practice at the centre as an alternative to antiplatelet therapy.
  • Antihypertensive treatment, if required, to achieve a target blood pressure < 140/90 mmHg (higher targets may be defined by the OMT committee for selected conditions, e.g. contralateral carotid occlusion) Application of structured programs, such as stepped-care approach using ranking of antihypertensive drugs will be used.
  • High-dose statin treatment (target LDL < 0.7 g/l). A stepped-care approach with raking of lipid-lowering drugs will also be used.
  • Patients smoking at the time of randomisation will be encouraged to stop and join a smoking cessation and support program.
  • Other lifestyle modification: reduction of alcohol consumption, choosing healthy food, increasing regular physical activity, reduction of body weight if relevant.

OMT may be modified during the course of the trial to take account revised guidelines or new evidence.

Being tested
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT), Optimal medical therapy alone
Keywords
Carotid stenosis,stroke,endarterectomy,medical therapy
Medical subject headings
Carotid Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)Other

    Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)

  • Optimal medical therapy aloneDrug

    Optimal medical therapy alone

Study groups in NCT02841098
Study groupRoleWhat they receive
Carotid endarterectomy combined with optimal medical therapyExperimentalCarotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
Receives: Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
Optimal medical therapy (OMT)Active comparatorOptimal medical therapy (OMT)
Receives: Drug: Optimal medical therapy alone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ipsilateral stroke or procedural stroke or death

    Any ipsilateral stroke within 6 years after randomization or procedural (within 30 days after revascularization) stroke or death

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

Secondary outcomes (19)
  1. Any stroke or procedural death

    Any stroke within 6 years after randomization or procedural death (within 30 days after revascularization)

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  2. Any disabling or fatal stroke or procedural death

    Any disabling or fatal stroke within 6 years after randomization or procedural death (within 30 days after revascularization)

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  3. Any stroke or TIA or procedural death

    Any stroke or TIA within 6 years after randomization or procedural death within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  4. Any stroke or death

    Any stroke or death within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  5. Myocardial infarction

    Myocardial infarction within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  6. Any death

    Any death within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  7. Cardiovascular death

    Cardiovascular death within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  8. Any hospitalisation for vascular disease

    Any hospitalisation for vascular disease within 6 years after randomization

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  9. Cranial nerve palsy attributed to revascularisation

    Cranial nerve palsy attributed to revascularisation within 30 days after revascularization

    Measured: M1

  10. Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay

    Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay within 30 days after revascularization

    Measured: M1

  11. Further revascularisation of the randomised artery after the initial attempt.

    Further revascularisation of the randomised artery after the initial attempt.

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  12. Carotid revascularisation

    Carotid revascularisation during follow-up other than that allocated at randomisation

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

  13. New cerebral infarction or haemorrhage

    New cerebral infarction or haemorrhage on MRI at 2 years

    Measured: M24

  14. Increase in white-matter changes

    Increase in white-matter changes on MRI at 2 years.

    Measured: M0, M24

  15. Cognitive impairment

    Cognitive impairment assessed by the Montreal Cognitive Assessment (MoCA) with adjustment for demographic factors.

    Measured: M0, M24

  16. Depression

    Depression measured by the Centre for Epidemiologic Studies Depression (CES-D) Scale.

    Measured: M0, M24

  17. Health-related quality of life

    Health-related quality of life measured using the European Quality Of Life (EQ-5D).

    Measured: M0, M24

  18. Disability

    Disability measured by the modified Rankin scale with structured interview

    Measured: M0, M24

  19. Achievement of goals for each of the components of optimal medical treatment

    Achievement of goals for each of the components of optimal medical treatment

    Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2016 (estimated)
  2. Study start16 Sep 2019
  3. Primary completion13 Jan 2022
  4. Study completion13 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
43 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02841098
Sponsor's protocol ID
D15-P010
Acronym
ACTRIS
Status last verified
Jul 2024
First submitted
19 Jul 2016
Last updated
11 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone in people with Asymptomatic Carotid Artery Stenosis, run by Centre Hospitalier St Anne at 23 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 23 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ipsilateral stroke or procedural stroke or death (time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in